T2 Biosystems, Inc. TTOO

TTOO Company Overview

T2 Biosystems, Inc. is a U.S.-based in vitro diagnostics company focused on the detection of sepsis-causing pathogens and antibiotic resistance markers directly from whole blood and other patient samples. The company operates in the molecular diagnostics and infectious disease testing industries, with a primary emphasis on rapid diagnostic technologies designed to improve clinical decision-making in critical care settings. Its core commercial platform is the T2Dx Instrument, which uses proprietary T2 Magnetic Resonance (T2MR) technology to identify pathogens without the need for traditional blood culture growth. Revenue has historically been generated through sales of instruments, reagent test panels, service contracts, and related consumables.

The company’s principal product lines include the T2Bacteria Panel, T2Candida Panel, and T2Resistance Panel, which are intended to detect bloodstream infections and antimicrobial resistance genes more rapidly than conventional laboratory methods. T2 Biosystems primarily serves hospitals, intensive care units, reference laboratories, and healthcare systems seeking faster sepsis diagnostics and antimicrobial stewardship tools. Founded in 2006 and headquartered in Lexington, Massachusetts, the company evolved from research centered on magnetic resonance applications in diagnostics and later commercialized its technology platform following regulatory clearances from the U.S. Food and Drug Administration. Its strategic positioning has centered on rapid direct-from-blood testing, which differentiates it from conventional culture-based microbiology workflows.